Prostate Cancer | Specialty

Optimizing Prevention of MACEs in Prostate Cancer

March 25th 2019

Standard of Care in Metastatic Prostate Cancer

March 25th 2019

Real-World Patients With High Risk of MACEs

March 25th 2019

GnRH Antagonists Versus GnRH Agonists

March 25th 2019

Effects of ADT on Morbidity and Mortality

March 25th 2019

Data Supporting the Risk of MACEs in ADT

March 25th 2019

Adverse Effects of Hormone Therapy in Prostate Cancer

March 25th 2019

The Cardioprotective Role of Androgens

March 25th 2019

Cardio-Oncology and Prostate Cancer

March 25th 2019

NCCN Guidelines Update Increases Role of Genetic Testing in Prostate Cancer

March 23rd 2019

Emmanuel S. Antonarakis, MD, discusses the prevalence of mismatch repair and homologous recombination deficiency genes and how they may play a role in determining a patient’s treatment plan in addition to promising agents that have been introduced to the field in clinical trials.

Dr. Slovin Discusses History of Immunotherapy in Prostate Cancer

March 22nd 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the history of immunotherapy in the treatment of patients with prostate cancer.

Dr. Gomella Discusses Role of BRCA1/2 in Prostate Cancer

March 22nd 2019

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of BRCA1/2 in patients with prostate cancer.

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC

March 14th 2019

AR-V7 protein in circulating tumor cells is a predictive marker of shorter progression-free and overall survival with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer.

Dr. Scholz on Significance of ARAMIS Trial in CRPC

March 13th 2019

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with metastatic castration-resistant prostate cancer.

Posadas Breaks Down Rapidly Evolving Prostate Cancer Paradigm

March 8th 2019

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.

Dr. Dorff on PARP Inhibitors in Prostate Cancer

March 7th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

BCL-2 Emerges as an Attractive Target in Solid and Hematologic Cancers

March 6th 2019

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

Japanese Approval Sought for Darolutamide in CRPC

March 6th 2019

An application has been submitted to Japan's Ministry of Health, Labor and Welfare for darolutamide for the treatment of patients with castration-resistant prostate cancer.

Personalized Medicine Is Next Step in Castration-Resistant Prostate Cancer

March 4th 2019

Raoul S. Concepcion, MD, FACS, discusses the clinical implications of the findings from the ARAMIS trial and highlights other therapies that are coming down the pike for the treatment of patients with castration-resistant prostate cancer.

Dr. Fleming Discusses Importance of QoL in Prostate Cancer

March 2nd 2019

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life in recent prostate cancer clinical trials.